Tenax Therapeutics entered into a supply agreement with Orion Corporation, making Orion the primary manufacturer and supplier of the oral version of its heart drug levosimendan. At the same time, the companies amended their license agreement to push back the deadline for U.S. regulatory approval to December 31, 2035. The supply deal runs for five years after the first delivery, with automatic three-year renewals unless either party gives 24 months' notice to stop.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding TENAX THERAPEUTICS INC (TENX)?

Major stakeholders currently include Price T Rowe Associates INC /md/ ($47.2M), Janus Henderson Group PLC ($29.1M), Venrock Adviser, LLC ($26.8M). Based on the latest 13F filings, there are a total of 80 tracked investment funds and institutions maintaining positions in TENX.

What is the overall institutional sentiment toward TENX recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $256.8M, driven by 57 managers accumulating shares while 6 reduced their exposure.

Which institutions have been selling or reducing their TENX positions?

In the latest period, 5 funds trimmed their holdings, and 1 managers completely exited their positions. The aggregate reported sell value was $11.1M.

Are there any notable investors adding TENX to their portfolios?

Yes, buying activity remains notable. 31 institutions opened new positions in {ticker}, and 26 existing holders added to their shares. The total reported buy value for the quarter amounted to $304.0M.